Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3038491 Target Snapshot

JAK3/JAK1 · PROTEIN COMPLEX · Homo sapiens

229Compounds
84Assays
8Approved Drugs
331.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P52333. Use UniProt P52333 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P52333 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats JAK3/JAK1 as ChEMBL target CHEMBL3038491, mapped to UniProt P52333. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
JAK3/JAK1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3038491
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P52333
Tyrosine-protein kinase JAK3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether JAK3/JAK1 is the right protein anchor across sources, using UniProt P52333 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase JAK3
UniProt AccessionP52333
Component TypeProtein
Sequence Length1124 aa

Tyrosine-protein kinase JAK3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as JAK3/JAK1, mapped to UniProt P52333. ChEMBL maps the protein component as Tyrosine-protein kinase JAK3. Sequence length is 1124 aa.

Mapped IDP52333
Review nameJAK3/JAK1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
1
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC50320.0
EC5011.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3622821 8.7 IC50 2.0 Approved
CHEMBL4588333 8.59 IC50 2.6 Preclinical
CHEMBL2105759 8.3 IC50 5.0 Approved
CHEMBL221959 8.17 IC50 6.7 Approved
CHEMBL4439418 8.15 IC50 7.1 Preclinical
CHEMBL4635876 8.1 IC50 7.943 Preclinical
CHEMBL5209379 8.05 IC50 9.0 Preclinical
CHEMBL5170161 8.05 IC50 9.0 Preclinical
CHEMBL4297507 8.05 IC50 9.0 Clinical
CHEMBL4437638 8.03 IC50 9.4 Preclinical
Distribution

pChEMBL Value Distribution

18
5.0
23
5.5
51
6.0
57
6.5
77
7.0
40
7.5
10
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DEUCRAVACITINIB
CHEMBL4435170
Approved 2022
ABROCITINIB
CHEMBL3655081
Approved 2021
FILGOTINIB
CHEMBL3301607
Approved 2020
UPADACITINIB
CHEMBL3622821
Approved 2019
BARICITINIB
CHEMBL2105759
Approved 2017
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
Assay Landscape

Assay Landscape

84
Total Assays
235
Tested Compounds
2
Assay Types
Binding — 76 assays, 235 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 53 132 7.0
protein complex format 12 67 6.8
tissue-based format 9 35 6.0
assay format 2 1 5.9
ADME — 8 assays, 5 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 5 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine